This is a prospective, longitudinal study involving 300 participants for a single visitto compare Long COVID neurocutaneous biosignatures with those of other disordersaffecting the sensory and autonomic nervous system.
This is a prospective, longitudinal study involving 300 participants for a single visit
to compare Long COVID neurocutaneous biosignatures with those of other disorders
affecting the sensory and autonomic nervous system. The evaluations will include clinical
assessments, neurologic exams, patient reported outcome surveys, and skin biopsies from
three locations. Data will be collected on the amount of P-SYN in cutaneous nerve fibers.
The cohorts of interest are as follows:
1. 100 participants with Long COVID defined by NIH PASC criteria
2. 100 participants with acute COVID who tested positive for COVID without persistent
symptoms defined WHO criteria
3. 50 participants with postural orthostatic tachycardia syndrome (POTS)
4. 50 participants with diabetic neuropathy
There are no plans for additional visits at this time.
If interested to learn more about this study, please complete the form here for someone
to contact you. "here" would take you to the said form.
Inclusion Criteria:
1. Long COVID defined by NIH PASC criteria OR 2. Acute COVID who tested positive for
COVID without persistent symptoms OR 3. Postural orthostatic tachycardia syndrome
(POTS) OR 4. Diabetic neuropathy
Exclusion Criteria:
1. Clinical evidence of severe peripheral vascular disease 2. History of ulceration,
poor wound healing or vascular claudication 3. History of allergic reaction to local
anesthesia (for biopsy collection) 4. Use of oral anticoagulants (aspirin or Plavix
alone is allowed) 5. History of a bleeding disorder
CND Life Sciences
Scottsdale, Arizona, United States
Investigator: Aracely Galarza
Contact: 4808470312
agalarza@cndlifesciences.com
Investigator: Todd Levine, MD
Aracely Galarza
480-434-6446
clinicalresearch@cndlifesciences.com
Not Provided